GSK Lays Out Five-Year Growth Strategy, Underpinned By Advair Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
The company’s five-year forecast includes the entry of Advair generics for the first time, but CEO Andrew Witty says pharma sales will nonetheless grow at low single-digits from 2016 to 2020.
You may also be interested in...
ViiV IPO Plans Ditched By GSK; New Plan Is To Retain Value
The British health care company has decided not to spin out a minority stake in its fast-growing HIV joint venture, in part because of feedback from investors against the idea.
GSK Gets New Start For Breo With FDA Approval In Asthma
FDA approved Breo Ellipta as a once-daily treatment for asthma, a new indication for a drug that has been on the market since October 2013 for COPD.
Swapping Assets Now Down To Execution For GSK And Novartis
Being successful with products originally marketed by the other will be key to the future growth and bragging rights for two leading European Big Pharmas, GlaxoSmithKline and Novartis.